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Familial dysautonomia (FD; also known as “Riley-Day syndrome”), an Ashkenazi Jewish disorder, is the best
known and most frequent of a group of congenital sensory neuropathies and is characterized by widespread sensory
and variable autonomic dysfunction. Previously, we had mapped the FD gene, DYS, to a 0.5-cM region on chro-
mosome 9q31 and had shown that the ethnic bias is due to a founder effect, with 199.5% of disease alleles sharing
a common ancestral haplotype. To investigate the molecular basis of FD, we sequenced the minimal candidate
region and cloned and characterized its five genes. One of these, IKBKAP, harbors two mutations that can cause
FD. The major haplotype mutation is located in the donor splice site of intron 20. This mutation can result in
skipping of exon 20 in the mRNA of patients with FD, although they continue to express varying levels of wild-
type message in a tissue-specific manner. RNA isolated from lymphoblasts of patients is primarily wild-type, whereas
only the deleted message is seen in RNA isolated from brain. The mutation associated with the minor haplotype
in four patients is a missense (R696P) mutation in exon 19, which is predicted to disrupt a potential phosphorylation
site. Our findings indicate that almost all cases of FD are caused by an unusual splice defect that displays tissue-
specific expression; and they also provide the basis for rapid carrier screening in the Ashkenazi Jewish population.
Introduction
Familial dysautonomia (FD; also known as “Riley-Day
syndrome” or as “hereditary sensory and autonomic
neuropathy type III” [MIM 223900]) is an autosomal
recessive disorder present in 1/3,600 live births in the
Ashkenazi Jewish population. This debilitating disorder
is due to the poor development, survival, and progressive
degeneration of the sensory and autonomic nervous sys-
tem (Axelrod et al. 1974). FD was first described in
1949, on the basis of five children who presented with
defective lacrimation, excessive sweating, skin blotching,
and hypertension (Riley et al. 1949). The following car-
dinal criteria have evolved for diagnosis of FD: absence
of fungiform papillae on the tongue, absence of flare
after injection of intradermal histamine, decreased or
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absent deep-tendon reflexes, absence of overflow emo-
tional tears, and Ashkenazi Jewish descent (Axelrod
1984; Axelrod and Pearson 1984).
The loss of neuronal function in FD has many re-
percussions, with patients displaying gastrointestinal
dysfunction, abnormal respiratory responses to hypoxic
and hypercarbic states, scoliosis, gastroesophageal re-
flux, vomiting crises, lack of overflow tears, inappro-
priate sweating, and postural hypotension (Riley et
al.1949; Axelrod et al.1974; Axelrod 1996). Despite
recent advances in the management of FD, the disorder
is inevitably fatal, with only 50% of patients reaching
age 30 years. The clinical features of FD are due to a
genetic defect that causes a striking, progressive deple-
tion of unmyelinated sensory and autonomic neurons
(Pearson and Pytel 1978a, 1978b; Pearson et al. 1978;
Axelrod 1995). This neuronal deficiency begins during
development, since extensive pathology is evident even
in the youngest subjects. Fetal development and post-
natal maintenance of dorsal-root ganglion (DRG) neu-
rons is abnormal, significantly decreasing their numbers
and resulting in DRG of grossly reduced size. Slow pro-
gressive degeneration is evidenced by continued neu-
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Figure 1 Genomic structure of IKBKAP, showing orientation and placement of the 37 exons within a 68-kb genomic region of chromosome
9q31. The primers used for analysis of the splice defect are denoted as “18F” (exon 18), “19F” (exon 19), and “23R” (exon 23). The asterisks
(*) indicate the locations of the two mutations identified; the mutation associated with the major AJ haplotype is located at base pair 6 of
intron 20, whereas the mutation association with the minor AJ haplotype is located at base pair 73 of exon 19. The “4.8” and “5.9” designations
at exon 37 indicate the lengths (in kb) of the two IKBKAP messages that differ only in the length of their 3′ UTRs.
ronal depletion with increasing age. In the autonomic
nervous system, superior cervical sympathetic ganglia
are also reduced in size, because of a severe decrease in
the neuronal population.
Previously, we had mapped the FD gene, DYS, to an
11-cM region of chromosome 9q31 (Blumenfeld et al.
1993), which was then narrowed, by haplotype anal-
ysis, to !0.5 cM, or 471 kb (Blumenfeld et al. 1999).
There is a single major haplotype that accounts for
199.5% of all FD chromosomes in the Ashkenazi Jewish
(AJ) population. The recent identification of several sin-
gle-nucleotide polymorphisms (SNPs) in the candidate
interval has allowed us to further reduce the candidate
region, to 177 kb, by revealing a common core hap-
lotype shared by the major and one previously described
minor haplotype (Blumenfeld et al. 1999). Two minor
haplotypes with apparently independent mutational or-
igins have been found in four AJ patients with FD and
in one patient of mixed AJ/non-AJ ancestry, all of whom
are heterozygous for the major haplotype. The high fre-
quency of the major mutation, combined with the pres-
ence of only two additional haplotypes, makes FD
unique among the AJ diseases.
Material and Methods
Samples from Patients with FD
We collected blood samples from two major sources,
the Dysautonomia Diagnostic and Treatment Center at
New York University Medical Center and the Israeli Cen-
ter for Familial Dysautonomia at Hadassah University
Hospital, with approval from the institutional review
boards at these institutions and at Massachusetts General
Hospital and Harvard Medical School. Either F.B.A. or
C.M. diagnosed all patients, using established criteria. We
established Epstein-Barr virus–transformed lymphoblast
lines, using standard conditions. Fibroblast cell lines were
obtained from the Coriell Cell Repositories. RNA isolated
from postmortem brain tissue of patients with FD was
obtained from the Dysautonomia Diagnostic and Treat-
ment Center at New York University. We prepared ge-
nomic DNA, total RNA, and mRNA, using commercial
kits (Invitrogen and Molecular Research Center). Cyto-
plasmic protein was extracted from lymphoblasts, as de-
scribed elsewhere (Krappmann et al. 2000).
Identification of IKBKAP, and Mutation Analysis
Exon-trapping experiments with cosmids from our
physical map of the candidate region yielded five exons
that were used to screen a human frontal-cortex cDNA
library. Several cDNA clones were isolated and assem-
bled into a novel transcript, encoding a 1,332–amino
acid protein, that was later identified as IKBKAP (Cohen
et al. 1998). The complete 5.9-kb cDNA sequence of
IKBKAP has been submitted to GenBank, under acces-
sion number AF153419. For screening of mutations in
patients with FD, total lymphoblast RNA was reverse
transcribed, and overlapping sections of IKBKAP were
amplified by PCR and were sequenced. Evaluation of
the splicing defect was performed by use of the following
primers: 18F (GCCAGTGTTTTTGCCTGAG), 19F (C-
GGATTGTCACTGTTGTGC), and 23R (GACTGCTC-
TCATAGCATCGC) (fig. 1).
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DNA Sequencing
Sequencing was performed either by use of the
AmpliCycle sequencing kit (Applied Biosystems) or on
an ABI 377 automated DNA sequencer using the BigDye
terminator cycle sequencing kit (Applied Biosystems).
The control sequence of the candidate region was ob-
tained by construction of subclone libraries from BACs
and sequencing using vector-specific primers. The FD
sequence was generated by sequencing of cosmids from
a patient homozygous for the major FD haplotype, by
use of sequence-specific primers.
Expression Studies
Several human multiple-tissue northern blots (Clon-
tech) were hybridized by use of the following radioac-
tively labeled probes: IKBKAP exon 2, IKBKAP exons
18–20, IKBKAP exon 23, and a 400-bp fragment of the
IKBKAP 3′ UTR immediately following the stop codon.
Poly (A) RNA was isolated from lymphoblast lines
form patients and control individuals, was northern
blotted, and was hybridized by use of a probe repre-
senting the complete coding sequence of IKBKAP. Cy-
toplasmic protein extracted from lymphoblast cell lines
was western blotted and was detected by use of ECL
(Amersham) with an antibody raised against a peptide
comprising the extreme carboxyl terminus (amino acids
1313–1332) of human IKAP, the protein encoded by
IKBKAP (Krappmann et al. 2000).
Results
To identify DYS, we used exon trapping and cDNA se-
lection to clone and characterize all of the genes in the
471-kb candidate region: EPB41L8 (authors’ unpub-
lished data) or EHM2 (Shimizu et al. 2000), C9ORF4
(Chadwick et al. 1999a), C9ORF5 (Chadwick et al.
2000), CTNNAL1 (Zhang et al. 1998), a novel gene
with homology to the glycine-cleavage system–H pro-
teins (CG-8) (authors’ unpublished data), IKBKAP (Co-
hen et al. 1998), and ACTL7A and ACTL7B (Chadwick
et al. 1999b). Since FD is a recessive disorder, the a priori
expectation for the mutation was inactivation of one of
these genes. Consequently, we screened each of them for
mutations, by reverse transcriptase–PCR (RT-PCR) of
lymphoblast RNA of patients and by direct sequencing
of all coding regions. Although we identified many SNPs,
there was no evidence for a homozygous inactivating
mutation. We concluded, therefore, that the mutation
would be found in noncoding sequence, and we gener-
ated the control genomic sequence of the entire 471-kb
candidate region, using bacterial artificial chromosomes
from our physical map. Direct sequence prediction using
GENSCAN and comprehensive searches of the public
databases, using BLAST, did not reveal any additional
genes in the candidate region, beyond those found by
cloning methods. However, SNPs identified during our
sequence analysis enabled us to refine our haplotype
analysis and to narrow the candidate interval to 177 kb
shared by the major haplotype and the previously de-
scribed minor haplotype 1 (Blumenfeld et al. 1999). This
reduced interval contains five genes—CTNNAL1, CG-
8, IKBKAP, ACTL7A, and ACTL7B—all previously
screened by RT-PCR, without yielding any coding-se-
quence mutations. We therefore constructed a cosmid
library from a patient homozygous for the major hap-
lotype, assembled the minimal-coverage contig for the
now-reduced candidate interval, and generated the se-
quence of the mutant chromosome.
Comparison of the FD and control sequences revealed
152 differences (when simple sequence–repeat markers
are excluded), which include 26 variations in the length
of dTn tracts, 1 VNTR, and 125 base-pair changes. Each
of the 125 base-pair changes was tested in a panel of
50 individuals known, by segregation analysis in fam-
ilies with FD, to carry two non-FD chromosomes. Of
the 125 changes tested, only 1 was unique to patients
carrying the major FD haplotype. This TrC change is
located at base pair 6 of intron 20 in the IKBKAP gene
depicted in figure 1 and is shown in figure 2a. IKAP
was originally identified as an IkB kinase (IKK) com-
plex–associated protein that can bind both NF-kB–
inducing kinase and IKKs, through separate domains,
and assemble them into an active kinase complex (Co-
hen et al. 1998). Recent work, however, has shown
that IKAP is not associated with IKKs and that it plays
no specific role in cytokine-induced NF-kB signaling
(Krappmann et al. 2000); rather, IKAP has been shown
to be part of a novel multiprotein complex hypothesized
to play a role in general transcriptional regulation.
The IKBKAP gene contains 37 exons and encodes a
1,332-amino-acid protein. The full-length 5.9-kb cDNA
(GenBank accession number AF153419) covers 68 kb
of genomic sequence, with the start methionine encod-
ed in exon 2. IKBKAP previously had been assigned
to chromosome 9q34 (GenBank accession number
AF044195), but it clearly maps within the FD candidate
region of 9q31. Northern blot analysis of IKBKAP re-
vealed two mRNAs—one of 4.8 kb and one of 5.9 kb
(fig. 3a and b). The 4.8-kb mRNA has been reported
elsewhere (Cohen et al. 1998), whereas the second, 5.9-
kb message differs only in the length of the 3′ UTR and
is predicted to encode an identical 150-kD protein. As
seen in figure 3b, the putative FD mutation does not
eliminate expression of the IKBKAP mRNA in lym-
phoblasts of patient with FD.
A base-pair change at position 6 of the splice donor
site might be expected to result in skipping of exon 20
(74 bp), causing a frameshift and therefore producing
a truncated protein; however, initial inspection of our
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Figure 2 Demonstration of mutations in IKBKAP. a, Antisense sequence of the TrC mutation (indicated by arrows adjacent to lanes G
and A) at base pair 6 of intron 20, which is associated with the major FD haplotype. Lanes 1 and 2, patients with FD who are homozygous
for the major haplotype (homozygous GG); lane 3, patient with FD who is heterozygous for the major haplotype and minor haplotype 2
(heterozygous GA); lane 4, patient with FD who is heterozygous for the major haplotype and minor haplotype 3 (heterozygous GA); lanes 5
and 6, control individuals (homozygous AA). b, Heterozygosity for the GrC mutation (indicated by arrows adjacent to lanes G and C) at base
pair 73 of exon 19. Lane 1, patient with FD who is homozygous for the major haplotype (homozygous GG); lanes 2–4, patients with FD who
are heterozygous for the major haplotype and minor haplotype 2 (heterozygous GC); lane 5, patient with FD who is heterozygous for the major
haplotype and minor haplotype 3 (homozygous GG); lane 6, control individual (homozygous GG). c, Sequence of cDNA generated from the
RT-PCR of a patient with FD who is heterozygous for the major and minor 2 haplotypes. The arrow points to the heterozygous GrC mutation
in exon 19. The boundary of exons 19 and 20 is also indicated, illustrating that this patient expresses wild-type message that includes exon
20, despite the presence of the major mutation on one allele.
RT-PCR experiments in lymphoblast RNA from pa-
tients with FD, using primers located in exons 18 and
23 (fig. 1), showed a normal-length, 500-bp fragment
that contained exon 20 (fig. 4a), indicating that lym-
phoblasts from patients with FD express normal
IKBKAP message. The western blot shown in figure 4b
demonstrates that full-length IKAP protein is expressed
in these lymphoblasts from patients with FD; however,
since the antibody used was directed against the car-
boxyl-terminus of IKAP, it would not be expected to
detect any truncated protein, should the latter be pre-
sent. The presence of apparently normal IKAP in cells
of patients with FD is at odds with the expectation of
an inactivating mutation in this recessive disease.
In the absence of any evidence for a functional con-
sequence of the intron 20 sequence change, the only
alteration unique to FD chromosomes, we sought ad-
ditional genetic evidence to support the view that it
represents the FD mutation. The 658 FD chromosomes
that carry the major haplotype all show the TrC
change. In toto, we have now tested 887 chromosomes
that, because of their failure to cause the disorder when
present in individuals heterozygous for the major FD
haplotype, are definitively non-FD. None of these non-
FD chromosomes exhibits the TrC mutation, strongly
indicating that none of them is a rare polymorphism.
The frequency of the mutation in random AJ chromo-
somes was 14/1,012 (gene frequency 1/72; carrier fre-
quency 1/36), close to the expected carrier frequency,
1/32 (Maayan et al. 1987).
In view of the strong genetic evidence that this mu-
tation must be pathogenic, we postulated that its effect
might be tissue specific. We therefore examined RNA
extracted from the brain stem and temporal lobe of a
postmortem brain sample from a patient with FD. In
contrast to what was seen with FD lymphoblasts, RT-
PCR of the FD brain-tissue RNA, using primers in exons
19 and 23 (expected to produce a normal, 393-bp prod-
uct) revealed a 319-bp mutant product, indicating that
there was virtually complete absence of exon 20 from
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Figure 3 Northern blot analysis of IKBKAP. a, Human multiple-tissue northern blot hybridized with IKBKAP exon 2, showing the
presence of two messages, of 4.8 and 5.9 kb (northern blots hybridized with other IKBKAP probes yielded similar patterns). b, Northern blot
generated by use of mRNA isolated from lymphoblast cell lines: lanes 1, 2, and 5, patients with FD who are homozygous for the major
haplotype; lane 3, individual carrying two definitively non-FD chromosomes; lane 4, patient with FD who is heterozygous for the major haplotype
and minor haplotype 2; lane 6, control brain RNA (Clontech). The level of expression of IKBKAP mRNA relative to b-actin mRNA is quite
variable in lymphoblasts. No consistent increase or decrease in mRNA levels was observed between patients with FD who are homozygous for
the major haplotype, patients with FD who are heterozygous for the major haplotype and minor haplotype 2, and control individuals.
the IKBKAP mRNA (fig. 5, lanes 10 and 11). Since
additional FD autopsy material could not be obtained,
we performed intensive analyses of additional lympho-
blast and fibroblast cell lines, to determine whether exon
skipping could be detected. Fibroblast lines from pa-
tients who were homozygous for the major FD haplo-
type yielded variable results. Some primary fibroblast
lines displayed approximately equal expression of the
mutant and wild-type mRNAs, whereas others dis-
played primarily wild-type mRNA. In addition, exten-
sive examination of lymphoblast lines from additional
patients indicated that the mutant message could some-
times be detected at low levels. An example of both the
variability seen in FD fibroblasts and the presence of
the mutant message in some FD lymphoblasts is shown
in figure 5. In fact, close reexamination of figure 4a
shows a trace of the mutant band in two (lanes 1 and
2) of the three FD samples. The absence of exon 20 in
the FD brain RNA, as well as the preponderance of
wild-type mRNA in fibroblasts and lymphoblasts, in-
dicates that the major FD mutation acts by altering the
splicing of IKBKAP, in a tissue-specific manner.
To identify the mutations associated with minor hap-
lotypes 2 and 3 (Blumenfeld et al. 1999), we amplified
each IKBKAP exon, including adjacent intron sequence,
from genomic DNA. A single GrC change at base pair
2397 (base pair 73 of exon 19), which causes an ar-
ginine-to-proline missense mutation (R696P), was iden-
tified in all four patients with minor haplotype 2 (fig.
2b). This was subsequently confirmed by RT-PCR in
lymphoblast RNA, as shown in figure 2c, for a region
that crosses the exon 19/20 border. The PCR product,
generated from a patient with FD who is a compound
heterozygote with minor haplotype 2 and the major
haplotype, clearly shows, on the basis of heterozygos-
ity of the GrC point mutation in exon 19, that RNA
is being expressed equally from both alleles. However,
the RNA from the major-haplotype allele shows no ev-
idence for skipping of exon 20, which would be ex-
pected to produce a mixture of exon 20/21 sequence,
beginning at the end of exon 19. This confirms our
previous observation that lymphoblasts with the ma-
jor FD mutation produce a predominance of normal
IKBKAP transcript.
The R696P mutation is absent from 500 non-FD
chromosomes, and it has been seen in only 1/706 ran-
dom AJ chromosomes, in an individual who also carries
the minor haplotype. This mutation is predicted to dis-
rupt a potential threonine phosphorylation site at res-
idue 699, identified by Netphos 2.0 (Blom et al. 1999),
suggesting that it may affect regulation of IKAP. Inter-
estingly, the presence of this minor mutation is associ-
ated with a relatively mild disease phenotype, suggesting
that a partially functional IKAP protein may be ex-
pressed from this allele. No mutation has been identified
for minor haplotype 3, which represents the only non-
AJ putative FD chromosome.
Discussion
The data presented here establish that mutation in the
IKBKAP gene underlies FD. Our findings have direct
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Figure 4 RT-PCR analysis of the exon 20 region of IKBKAP, showing expression of the wild-type message and protein in patients. a,
Results of use of primers 18F (exon 18) and 23R (exon 23). Lanes 1 and 2, patients with FD who are homozygous for the major haplotype;
lane 3, patient with FD who is heterozygous for the major haplotype and minor haplotype 2; lanes 4 and 5, control individuals; lane 6, water
control. b, Results of western blot generated by use of cytoplasmic protein isolated from lymphoblast cell lines of patients with FD and detected
with a carboxyl-terminal antibody. Lane 1, patient with FD who is heterozygous for the major and minor haplotype 3; lanes 2, 4, 6, and 8,
patients with FD who are homozygous for the major haplotype; lanes 3, 5, 7, and 9, controls individuals; lane 10, patient with FD who is
heterozygous for the major and minor haplotype 2; lane 11, Hela cell–line sample.
Figure 5 RT-PCR analysis of the exon 20 region of IKBKAP,
showing variable expression of the mutant message in patients with
FD patients. The analysis was done by use of primers 19F (exon 19)
and 23F (exon 23). Lanes 1 and 2, control fibroblasts; lanes 3–5,
fibroblasts of patients with FD who are homozygous for the major
mutation; lanes 6 and 7, lymphoblasts of patients with FD who are
homozygous for the major mutation; lanes 8 and 9, control lympho-
blasts; lane 10, brain stem of patient with FD; lane 11, temporal lobe
of patient with FD (showing a faint 319-bp band and no 393-bp band);
lane 12, water control. RT-PCR of control brain RNA (Clontech)
showed only the 393-bp band (data not shown).
implications for understanding this devastating disorder,
for preventing it, and, potentially, for treating it. The
IKAP protein produced from IKBKAP originally had
been isolated as part of a large interleukin-1–inducible
IKK complex and had been described as a regulator of
kinases involved in proinflammatory cytokine signaling
(Cohen et al. 1998). However, a recent report questioned
this conclusion after demonstrating that cellular IKK
complexes do not contain IKAP, by using various pro-
tein-protein interaction and functional assays; rather,
IKAP appears to be a member of a novel complex con-
taining additional unidentified proteins, of 100, 70, 45,
and 39 kD (Krappmann et al. 2000).
IKAP is homologous to the Elp1 protein of Sacchar-
omyces cerevisiae, which is encoded by the IKI3 locus
and is required for sensitivity to pGKL killer toxin. The
human and yeast proteins exhibit 29% identity and
46% similarity over their entire lengths. Yeast Elp1 pro-
tein is part of the RNA polymerase II–associated elon-
gator complex, which also contains Elp2, a WD-40 re-
peat protein, and Elp3, a histone acetyltransferase
(Otero et al. 1999). The human ELP3 gene encodes a
60-kD histone acetyltransferase that shows 175% iden-
tity with yeast Elp3 protein, but no 60-kD protein has
been found in the human IKAP-containing protein com-
plex. Consequently, it is considered unlikely that IKAP
is a member of a functionally conserved mammalian
elongator complex (Krappmann et al. 2000). Instead,
it has been suggested that the protein may play a role
in general gene-activation mechanisms, since overex-
pression of IKAP interferes with the activity of both
NF-kB–dependent and independent reporter genes
(Krappmann et al. 2000). Therefore, the FD phenotype
may be caused by aberrant expression of genes crucial
to the development of the sensory and autonomic nerv-
ous systems, secondary to the loss of a functional IKAP
protein in specific tissues.
FD is unique among Ashkenazi Jewish disorders, in
that one mutation accounts for 199.5% of the disease
chromosomes. As in other autosomal recessive diseases
with no phenotype in heterozygous carriers, one might
have expected to find several different types of muta-
tions producing complete inactivation of the DYS gene
in the AJ population. The fact that the major FD mu-
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tation does not produce complete inactivation but,
rather, allows variable tissue-specific expression of IKAP
may explain this lack of mutational diversity. Mutations
causing complete inactivation of IKAP in all tissues
might cause a more severe or even lethal phenotype.
Indeed, CG10535, the apparent Drosophila melano-
gaster homologue of IKBKAP, maps coincident with a
larval recessive lethal locus (l(3)04629), supporting the
essential nature of the protein (FlyBase). Thus, the array
of mutations that can produce the FD phenotype may
be limited if, to permit survival, they must also allow
expression of functional or partially functional IKAP in
some tissues. With the identification of IKBKAP as
DYS, it will now be possible to test this inactivation
hypothesis in a mammalian model system.
Despite the overwhelming predominance of a single
mutation in patients with FD, the disease phenotype is
remarkably variable both within and between families.
The nature of the major FD mutation makes it tempting
to consider that this phenotypic variability might relate
to the frequency of exon 20 skipping in specific tissues
and at specific developmental stages, which may be gov-
erned by variations in many factors involved in RNA
splicing. Even a small amount of normal IKAP protein
expressed in critical tissues might permit sufficient neu-
ronal survival to alleviate the most severe phenotypes.
This possibility is supported by the relatively mild phe-
notype associated with the presence of the R696P mu-
tation, which is predicted to permit expression of an
altered full-length IKAP protein that may retain some
functional capacity. To date, this minor FD mutation
has been seen in only four patients heterozygous for the
major mutation. Consequently, it is uncertain whether
homozygotes for the R696P mutation would display
any phenotypic abnormality characteristic of FD. The
single patient with minor haplotype 3 and mixed an-
cestry, whose mutation has yet to be found, is also a
compound heterozygote with the major haplotype. The
existence of minor haplotype 3 indicates that IKBKAP
mutations will be found outside the AJ population, but,
as is also the case with the R696P mutation, it is difficult
to predict the severity of the phenotype that would result
from homozygosity.
The identification of IKBKAP as the DYS gene clearly
presents new possibilities for investigating the role that
IKAP and associated proteins have in the development
and maintenance of the sensory and autonomic nervous
systems. What is of more-immediate practical impor-
tance, however, is that the discovery of the single-base
mutation that characterizes 199.5% of FD chromo-
somes will permit efficient, inexpensive carrier testing
in the AJ population, to guide reproductive choices and
to reduce the incidence of FD. The nature of the major
mutation also offers some hope for new approaches to
the treatment of FD. Despite the presence of this mu-
tation, lymphoblastoid cells from patients with FD are
capable of producing full-length wild-type mRNA and
normal IKAP protein, whereas, in neuronal tissue, exon
20 is skipped, presumably leading to a truncated prod-
uct. Investigation of the mechanism that permits lym-
phoblasts to be relatively insensitive to the potential
effect that the mutation has on splicing may suggest
strategies to prevent skipping of exon 20 in other cell
types. An effective treatment to prevent the progres-
sive neuronal loss of FD may be one that is aimed at
facilitating the production of wild-type mRNA from
the mutant gene, rather than one aimed at exogenous
administration of the missing IKAP protein via gene
therapy.
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